new treatment for her2-positive breast cancer

Release time ：Dec-19,2024

New therapeutic approaches for HER2-positive breast cancer typically encompass advanced modalities such as targeted therapies and immunotherapies, potentially offering patients improved survival rates and quality of life. Targeted therapy plays a crucial role in treating HER2-positive breast cancer by employing specific drugs that identify and attack cancer cells overexpressing HER2 protein while minimizing harm to healthy cells. For instance, trastuzumab (Herceptin) is a widely utilized targeted therapy for HER2-positive breast cancer; it binds to HER2 protein on cancer cells, inhibiting their growth and spread. Additionally, pertuzumab (Perjeta) is another targeted therapy that binds to distinct regions of HER2, enhancing treatment efficacy. Immunotherapy has also seen significant advancements in the management of HER2-positive breast cancer. This approach aims to activate the patient's immune system to recognize and combat cancer cells. An example is T-DXd, an antibody-drug conjugate that links antibodies with chemotherapy agents, enabling more precise targeting of cancer cells and reducing damage to healthy cells. Lastly, for HER2-positive breast cancer patients, seeking timely medical attention and adhering to standardized treatment protocols is essential. Patients should select appropriate treatment plans under medical supervision and strictly follow treatment instructions. Furthermore, maintaining healthy lifestyle practices, such as a balanced diet and regular exercise, can enhance physical fitness and immune function, better equipping patients to face the various challenges encountered during treatment.